Table 7.
Author | N | T3-4 tumor n (%) | Positive node n (%) | Fractionation patterns for GTV | LCR (%) | ||||
---|---|---|---|---|---|---|---|---|---|
Fraction | Prescription dose (Gy) | Fraction dose (Gy) | BED* (Gy) OTT disregarded | BED* (Gy) | |||||
Lee SW (2005)12 | 20 | 8 (40) | 18 (90) | 30 | 72 | 2.4 | 89.3 | 69.5 | 88.0 (2-y) |
Lin SJ (2009)13 | 323 | 260 (80.5) | 293 (90.7) | 30 / 31 | 66 / 69.8 | 2.2 / 2.25 | 80.5 / 85.4 | 60.7 / 63.8 | 95.0 (3-y LRFS) |
RTOG0225 (2009)14 | 68 | 23 (33.8) | 50 (73.5) | 33 | 70 | 2.12 | 84.8 | 62.0 | 92.6 (2-y) |
Xiao WW (2011)15 | 81 | 81 (100) | 56 (69.1) | 30 | 68 | 2.27 | 83.4 | 63.6 | 94.9 (3-y) |
Bakst RL (2011)16 | 25 | 16 (64) | 20 (80) | 30 | 70.2 | 2.34 | 86.6 | 66.8 | 91.0 (3-y) |
Wang RS (2013)17 | 300 | 214 (71.3) | 277 (92.3) | 30–32 | 68–72 | 2.25–2.27 | 83.4–88.2 | 63.6–66.0 | 94.0 (4-y) |
Author (2014)3 | 190 | 68 (35.8) | 150 (78.9) | 33 | 70 | 2.12 | 84.8 | 62.0 | 96.1 (2-y LRFS) |
Current study | 132 | 55 (41.7) | 119 (90.2) | 30 | 67.5 | 2.25 | 82.7 | 62.9 | 96.7 (2-y LRFS) |
α/β = 10Gy; OTT = overall treatment time; LCR = local control rate; LRFS = local relapse-free survival; y = year